[The mTOR pathway: a new target for treating cognitive deficits of schizophrenia?].
Philippe
P
Marin
Julie
J
Meffre
Joël
J
Bockaert
D003072:Cognition Disorders / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology; D012559:Schizophrenia / Q000150:complications* / Q000503:physiopathology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D020123:Sirolimus / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*
D007166:Immunosuppressive Agents; D011985:Receptors, Serotonin; C097216:serotonin 6 receptor; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus